SCHEMBL2117901

SCHEMBL2117901

COc1ccc(S(=O)(=O)N(C)c2ccc(C)c(-c3ccoc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.48
CYP2C9 P11712 1/20 0.45
KEAP1 Q14145 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
KMT2A Q03164 1/20 0.42
NFE2L2 Q16236 3/20 0.41
MCOLN3 Q8TDD5 2/20 0.41
HTT P42858 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 3/20 0.41
MMP1 P03956 1/20 0.40
MMP9 P14780 1/20 0.40
MMP13 P45452 1/20 0.40
ADAM17 P78536 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119577 0.88 MAPT (0.54) CYP2C9L3MBTL1ALDH1A1NPSR1LMNA
SCHEMBL2117796 0.87 PGR (0.56) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2118113 0.83 MAPT (0.54) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2120055 0.80 PGR (0.51) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2120177 0.80 PGR (0.48) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2121835 0.79 STAT3 (0.52) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2120655 0.77 PGR (0.46) PGRCYP2C9KEAP1L3MBTL1ALDH1A1
SCHEMBL2121852 0.77 PGR (0.46) PGRCYP2C9KEAP1L3MBTL1NPSR1
SCHEMBL10035040 0.76 PPARG (0.48) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL2119835 0.76 PGR (0.46) PGRCYP2C9KEAP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 PGR 2683/4885CYP2C9 3693/4885KEAP1 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.